Skip to main content

Nurix Therapeutics, Inc. (NRIX) Stock Analysis

SellVALUE-TRAP 2/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $15.69: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum.

Nurix Therapeutics is a clinical-stage biopharma developing targeted protein degraders using its DEL-AI discovery platform. Its three wholly owned clinical candidates are bexobrutideg (BTK degrader, Phase 2 potentially pivotal for CLL), zelebrudomide (dual BTK/Ikaros/Aiolos... Read more

$15.69+78.2% A.UpsideScore 4.4/10#135 of 157 Biotechnology
QualityF-score3 / 9FCF yield-9.07%
Stop $14.62Target $27.16(analyst − 10%)A.R:R 8.0:1
Analyst target$30.18+92.3%17 analysts
$27.16our TP
$15.69price
$30.18mean
$41

Sell if holding. Engine safety override at $15.69: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.4/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val5.4Qual1.8Grw5.0Mom3.7Sent9.0Ins3.8Peer1.3Tech7.2Risk3.64.4OVERALL

Recent Developments — Nurix Therapeutics, Inc.

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
Recent Analyst detected in news
Risks
Quality below floor (1.8 < 4.0)
Value-trap signals (2/5): Margin compression (op margin -12.4%), Material insider selling (114 sells, 0.20% of cap)

Key Metrics

P/E (TTM)—
P/E (Fwd)-5.4
Mkt Cap$1.6B
EV/EBITDA-3.6
Profit Mgn0.0%
ROE-61.4%
Rev Growth-66.1%
Beta1.88
DividendNone
Rating analysts23

Quality Signals

Piotroski F3/9

Options Flow

P/C0.02bullish
IV96%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.4
Growth Rank
1.4
Value Rank
2.6

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
3.3
Moat
4.0
Current Ratio
7.0
Cash-burning: FCF -203% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.5
Obv
1.0
Ma Position
4.0
Volume
4.5
Rsi
8.5
Uptrend pullback (RSI 30) - buy opportunityVolume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.7<4.5A.R:R 8.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.70EARNINGS PROXIMITY 51d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
30 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $15.07Resistance $17.49

Price Targets

$15
$27
A.Upside+73.1%
A.R:R8.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.8 < 4.0)
! Value-trap signals (2/5): Margin compression (op margin -12.4%), Material insider selling (114 sells, 0.20% of cap)
! Momentum score 3.7/10 — below 4.5 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-07-09 (51d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is NRIX stock a buy right now?

Sell if holding. Engine safety override at $15.69: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $14.62. Score 4.4/10, moderate confidence.

What is the NRIX stock price target?

Take-profit target: $27.16 (+78.2% upside). Prior stop was $14.62. Stop-loss: $14.62.

What are the risks of investing in NRIX?

Quality below floor (1.8 < 4.0); Value-trap signals (2/5): Margin compression (op margin -12.4%), Material insider selling (114 sells, 0.20% of cap).

Is NRIX overvalued or undervalued?

Nurix Therapeutics, Inc. trades at a P/E of N/A (forward -5.4). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about NRIX?

23 analysts cover NRIX with a consensus score of 4.3/5. Average price target: $30.

What does Nurix Therapeutics, Inc. do?Nurix Therapeutics is a clinical-stage biopharma developing targeted protein degraders using its DEL-AI discovery...

Nurix Therapeutics is a clinical-stage biopharma developing targeted protein degraders using its DEL-AI discovery platform. Its three wholly owned clinical candidates are bexobrutideg (BTK degrader, Phase 2 potentially pivotal for CLL), zelebrudomide (dual BTK/Ikaros/Aiolos degrader, Phase 1/2), and NX-1607 (CBL-B inhibitor, Phase 1). Revenue comes entirely from collaborations with Gilead, Sanofi, and Pfizer; $482M received through November 2025.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · ADMA (ADMA Biologics Inc) · HALO (Halozyme Therapeutics, Inc.) · HRMY (Harmony Biosciences Holdings, I) · GLPG (Galapagos NV)